1,000+ Opportunities

Find the right grant

Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.

This listing may be outdated. Verify details at the official source before applying.

Find similar grants

ActiveIMI2 Joint Undertaking (EU/Industry) · 2026

IMI2 JU – Innovative Medicines Initiative Calls

Quick Facts

Agency: IMI2 Joint Undertaking (EU/Industry)
Funding: See RFP
Deadline: Check Source
Status: Active
Eligibility: Consortia including SMEs, large industry, academic institutions, and non-profits (EU or associated countries).
Geographic Scope: European Union And Horizon Europe Associated Countries

VerifiedGrant verified by AI review

About This Grant

IMI2 JU – Innovative Medicines Initiative Calls is sponsored by IMI2 Joint Undertaking (EU/Industry). Funds collaborative infectious disease research, including accurate/rapid pathogen diagnostics in the EU via public-private partnerships.

Visit Funder Website

Get a weekly digest of new grants like this

A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.

Or search similar grants →

Official Opportunity Details

Extracted from the official opportunity page/RFP to help you evaluate fit faster.

* ESMO Award for Translational Research * ESMO Women for Oncology Award * ESMO Lifetime Achievement Award * ESMO Breast Cancer Award * ESMO Award for Immuno-Oncology * Organisational Structure * Annals of Oncology Editorial Board * Cancer Therapies Committee * ESMO-Magnitude of Clinical Benefit Scale Working Group * Communication Committee * Compliance and Ethics Committee * Digital Education Committee * Adolescents and Young Adults Task Force * Designated Centres Task Force * Educational Publications Task Force * ESMO Precision Oncology Task Force * ESMO SIOG Cancer in the Elderly Task Force * Examination & Accreditation Working Group * ESMO Community Oncologists Task Force * Real World Data and Digital Health Task Force * ESMO Gastrointestinal Oncology Editorial Board * ESMO Industry Strategic Forum * ESMO Open Editorial Board * ESMO Rare Cancer Editorial Board * ESMO Real World Data and Digital Oncology Editorial Board * Leadership Development Committee * National Societies Committee * Women for Oncology Committee * Young Oncologists Committee * ESMO Members: Get Involved * Early Detection and Prevention of Cancer Task Force * Gender Medicine Task Force * Climate Change Task Force * Clinical Research Observatory Task Force (ECRO) * Acknowledgements: Rationalizing Bureaucracy * Bibliography on Clinical Trial Procedures * Declaration of Interest * Notice of the 2025 Ordinary Annual General Assembly Vote * About Annals of Oncology * Annals of Oncology 35th Anniversary * Frequently Asked Questions * Immuno-Oncology and Technology * ESMO Gastrointestinal Oncology * ESMO Real World Data and Digital Oncology * ESMO Affiliated Journals * Cancer Treatment Reviews * Clinical Lymphoma Myeloma and Leukemia * COVID-19 and cancer care in the ESMO journals * Frequently Asked Questions * Looking ahead, honouring the past * Embracing a year of strong collaboration and steady progress * Stepping into the shoes of a Society with a global footprint * ESMO for World Cancer Day 2026 * ESMO for World Cancer Day 2025 * ESMO for World Cancer Day 2024 * ESMO for World Cancer Day 2023 * ESMO for World Cancer Day 2022 * Membership Categories & Annual Fees * ESMO Guidelines Methodology * Pan-Asian Guidelines Adaptation (PAGA) * Pocket Guidelines & Mobile App * ESMO-MCBS Online Tutorials * ESMO-MCBS for Solid Tumours * ESMO-MCBS for Haematological Malignancies * Cancers of Unknown Primary Site * Endocrine and Neuroendocrine Cancers * Gastrointestinal Cancers * Haematological Malignancies * Melanoma and Skin Cancers * Supportive and Palliative Care * ESMO Statements on vaccination against COVID-19 * ESMO Preceptorship Courses * ESMO Courses in Medical Oncology for Medical Students * ESMO Best Student Award * ESMO Fellowship Programme * Benefits for Institutes * Translational Research Unit Visits * External Oncology Fellowship Opportunities * About Oncology Fellowships * Young Oncologists Corner * YO4YO Virtual Session Series * About Young Oncologists Corner * Considering a Career Abroad?

* Sample Exam Questions Explained * ESMO-MORA Recertification Process and Requirements * CME Tests for Handbooks * ESMO Certificate of Professional Development * W4O Sessions and Events * ESMO Leadership Programme * Leaders Generation Programme Asia * Travel Grants for ESMO Meetings * About Career Development * ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) * ESMO Guidance for Reporting Oncology real-World Evidence (ESMO-GROW) * ESMO Tumour-Agnostic Classifier and Screener * ESMO Basic Requirements for AI-based Biomarkers in Oncology * ESMO Guidance on the Use of Large Language Models in Clinical Practice (ELCAP) * About the Grant Schemes * Clinical Research Observatory Task Force (ECRO) * Acknowledgements: Rationalizing Bureaucracy * Bibliography on Clinical Trial Procedures * Research Funding opportunities * ESMO Webinar: EU Research Opportunities * How to Apply For EU Grants * Other Research Funding Opportunities * Research Groups, Tools and Database * Cancer research groups by type * General research groups * COVID-19 and Cancer: Registries, Studies and Surveys * Resources for Patients with Cancer * ESMO Designated Centres of Integrated Oncology and Palliative Care * 2025 ESMO Designated Centres * Palliative and Supportive Care Sessions at ESMO Congress 2025 Berlin * ESMO Designated Centres * ESMO Designated Centres Programme * Designated Centres Surveys * Cancer Care During the COVID-19 Pandemic * Krebstherapie während der COVID-19-Pandemie * Supportive Care Glossary * Palliative Care Glossary * Gastro-Oesophageal Cancer * Hepatocellular Carcinoma * Aggressive Lymphoma Management * B-cell non-Hodgkin Lymphoma * Urothelial Bladder Cancer * Traitement du Cancer au Cours de la Pandémie de COVID-19 * Le Cure per il Cancro Durante la Pandemia da COVID-19 * Cuidado del cáncer durante la pandemia de COVID-19 * Patient Guides by Language * Immunotherapy Side Effects * Personalised Cancer Medicine * Personalised Medicine Explained * Getting the Most out of Your Oncologist * ESMO Patient Engagement Summit * Public Policy Committee * Patient Advocates Working Group * Rare Cancers Working Group * ESMO Public Policy Track and Special Sessions * ESMO AI & Digital Oncology Hub * News and Expert Insights * Regulatory and Ethical Aspects ESMO is a Swiss-registered not-for-profit organisation.

All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH [](https://www. facebook.

com/esmo. org) [](https://www. youtube.

com/user/ESMOchannel) [](https://www. esmo. org/rss/feed/esmo-news) [](https://www.

linkedin. com/company/european-society-for-medical-oncology/posts/? feedView=all) [](https://www.

instagram. com/esmo_eur_oncology/)

Eligibility Requirements

Consortia including SMEs, large industry, academic institutions, and non-profits (EU or associated countries).

Frequently Asked Questions

Who can apply for IMI2 JU – Innovative Medicines Initiative Calls?

According to the current listing, eligibility includes: Consortia including SMEs, large industry, academic institutions, and non-profits (EU or associated countries). Confirm the full requirements in the official notice before applying.

Who funds IMI2 JU – Innovative Medicines Initiative Calls?

IMI2 JU – Innovative Medicines Initiative Calls is funded by IMI2 Joint Undertaking (EU/Industry). Verify program details on the funder's official page before applying.

How do I apply for IMI2 JU – Innovative Medicines Initiative Calls?

Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.

Funder Profile

Ready to start your proposal?

Granted drafts, reviews, and strengthens your grant application — saving weeks of work. Professional members win a grant in 12 months or get a full refund.

Browse More Grants

Backed by the Granted Guarantee

IMI2 Joint Undertaking (EU/Industry) Grant Writing Tips

NSF Gave $47 Million to a Nonprofit Instead of Running a Competition. The I-PhD Scholars Program Rebuilds the Doctorate Around a $100,000 Company Check.

NSF's Industry-Integrated PhD Scholars Program commits $47 million over five years through the nonprofit UIDP to place more than 250 doctoral students in year-long industry research placements. Universities fund year one, NSF funds years two through four, and each company puts in at least $100,000 per student. Here is what the funding structure actually selects for, the four-year timeline problem, and what universities, companies, and students should do.

Read article

State's Garment Labor Rights NOFO Has One Award, a Fixed Price, and a Country List Drawn by Trade Policy. It Closes August 27.

DRL's Advancing Labor Rights in the Garment Industry opportunity (DFOP0019477) offers exactly $986,500 — floor and ceiling identical — for a single 24-month award. Eligibility is scoped to countries with signed Agreements on Reciprocal Trade with the United States, and Bangladesh is explicitly excluded. That design tells you more about the program than the funding amount does.

Read article

DOE's $58 Million ASPECT NOFO Drops August 24. The Teaming Rule Buried in the Notice of Intent Decides Who Can Even Apply.

The Alternative Fuels and Feedstocks Office issued a Notice of Intent on July 14 for ASPECT — up to $58 million in cooperative agreements for producing chemicals from alternative and waste feedstocks, with the full NOFO expected August 24, 2026. Two topic areas, four sub-topics, 2-to-5-year performance periods, a required concept paper, and one requirement most applicants will miss: every project needs a for-profit industry partner, and universities cannot lead Topic Area 2. Here is how to use the pre-NOFO window.

Read article